The present disclosure relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and/or factor XIIa to prevent the formation and/or the stabilization of threedimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.